Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625755 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00625755 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT00625755, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will look how using taken from your tumors and mixed with special immune stimulating cells from another person's blood in given back to you in a series "fusion cell" injections, will effect your body. The primary goal of the study is to see if giving the experimental fusion cell injections is safe. We will also be looking to see what effect the experimental treatment as on your immune system and whether it has an effect on your cancer.
Interventions
- BIOLOGICAL Electrofusion DC vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00625755
The ClinicalTrials.gov registry entry for NCT00625755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Electrofusion DC vaccine is the first listed.
NCT00625755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00625755 about?
NCT00625755 is a clinical study titled "A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma". This study will look how using taken from your tumors and mixed with special immune stimulating cells from another person's blood in given back to you in a series "fusion cell" injections, will effect your body. The primary goal of the study is to see if giving the experimental fusion cell injection...
What is the current status of trial NCT00625755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-12. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00625755?
The interventions under investigation include: Electrofusion DC vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00625755?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.